Literature DB >> 29352729

Voxelotor (GBT440), a first-in-class hemoglobin oxygen-affinity modulator, has promising and reassuring preclinical and clinical data.

Jeremie H Estepp1,2,3.   

Abstract

Mesh：

Substances：

Year:  2018        PMID： 29352729     DOI： 10.1002/ajh.25042

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  3 in total

Review 1.  Time Domains of Hypoxia Responses and -Omics Insights.

Authors:  James J Yu; Amy L Non; Erica C Heinrich; Wanjun Gu; Joe Alcock; Esteban A Moya; Elijah S Lawrence; Michael S Tift; Katie A O'Brien; Jay F Storz; Anthony V Signore; Jane I Khudyakov; William K Milsom; Sean M Wilson; Cynthia M Beall; Francisco C Villafuerte; Tsering Stobdan; Colleen G Julian; Lorna G Moore; Mark M Fuster; Jennifer A Stokes; Richard Milner; John B West; Jiao Zhang; John Y Shyy; Ainash Childebayeva; José Pablo Vázquez-Medina; Luu V Pham; Omar A Mesarwi; James E Hall; Zachary A Cheviron; Jeremy Sieker; Arlin B Blood; Jason X Yuan; Graham R Scott; Brinda K Rana; Paul J Ponganis; Atul Malhotra; Frank L Powell; Tatum S Simonson
Journal:  Front Physiol       Date:  2022-08-08       Impact factor: 4.755

2.  Case report: Safety and efficacy of voxelotor in a patient with sickle cell disease and stage IV chronic kidney disease.

Authors:  Awni Alshurafa; Mohamed A Yassin
Journal:  Front Med (Lausanne)       Date:  2022-09-15

3.  Sulfated non-anticoagulant heparin derivative modifies intracellular hemoglobin, inhibits cell sickling in vitro, and prolongs survival of sickle cell mice under hypoxia.

Authors:  Osheiza Abdulmalik; Noureldien H E Darwish; Vandhana Muralidharan-Chari; Maii Abu Taleb; Shaker A Mousa
Journal:  Haematologica       Date:  2022-02-01       Impact factor: 9.941
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.